Valion Bio, Inc. (VBIO)
| Market Cap | 2.68M -19.3% |
| Revenue (ttm) | n/a |
| Net Income | -19.23M |
| EPS | -8.41 |
| Shares Out | 22.19M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,061,788 |
| Open | 0.1226 |
| Previous Close | 0.1226 |
| Day's Range | 0.1167 - 0.1340 |
| 52-Week Range | 0.1116 - 3.2080 |
| Beta | 1.86 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About VBIO
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company’s pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in Apr... [Read more]
Financial Performance
Financial StatementsNews
Valion Bio Inc trading halted, news pending
19:50 EDT Valion Bio (VBIO) Inc trading halted, news pending
Valion Bio announces 1-for-25 reverse stock split
Valion Bio (VBIO) announced that its Board of Directors has declared a 1-for-25 reverse stock split of the Company’s issued and outstanding shares of common stock. The purpose of the…
Valion Bio Announces Reverse Stock Split
SAN ANTONIO, TX / ACCESS Newswire / August 27, 2026 / Valion Bio, Inc. (Nasdaq:VBIO) ("Valion Bio" or the "Company) announced today that its Board of Directors has declared a 1-for-25 reverse stock sp...
Valion Bio announces U.S. government-funded entolimod studies
Valion Bio (VBIO) announced that the Armed Forces Radiobiology Research Institute, under its contract with the National Institute of Allergy and Infectious Diseases, is conducting a U.S. Department of...
Valion Bio says Ukraine Ministry of Health accepts entolimod regulatory dossier
Valion Bio (VBIO) announced that Ukraine’s Ministry of Health has accepted the Company’s regulatory dossier for Entolimod for formal review under the country’s Regulatory Equivalence Pathway. Entolimo...
Valion Bio Quarterly report: Q2 2026
Valion Bio has published its Q2 2026 quarterly earnings report on August 14, 2026.
Valion Bio Transcript: EGM 2026
Shareholders considered two proposals: granting the Board authority for a reverse stock split and the ability to adjourn the meeting if needed. Both proposals received preliminary approval, with final results to be filed with the SEC.
Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase
Potential Fourth-Quarter 2026 Decision Could Mark Entolimod's First National Registration and Open a Pathway to Strategic Stockpiling and Government Procurement Formal review accepted July 22 • Minist...
Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury
AFRRI/NIAID Program to Advance Safety and Therapeutic Studies in Rapid Sequence; Top-Line Therapeutic Data Expected in Early Fall Study drug delivered • IACUC approval secured • Safety study planned t...
Valion Bio’s regulatory dossier for Entolimod accepted for review in Ukraine
Valion Bio (VBIO) announced that Ukraine’s Ministry of Health, or MoH, has accepted the Company’s regulatory dossier for Entolimod for formal review under Ukraine’s Regulatory Equivalence Pathway, fol...
Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway
Government acceptance initiates formal regulatory review of Entolimod under Ukraine's Regulatory Equivalency pathway, with a potential review expected in as few as 45- to 60-days. Ukraine Ministry of ...
World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market
Sheba Medical Center, which is ranked the #7 hospital in the world, has chosen to evaluate and fund a trial of Valion Bio's Entolimod in cancer patients, creating a second clinical development pathway...
Valion Bio files to sell 29.41M shares of common stock, warrants
Dawson James Securities is acting as sole placement agent.
Valion Bio Registration statement: Registration filing
Valion Bio filed a registration statement on July 17, 2026, providing details about a securities offering with the SEC.
Valion Bio Proxy statement: Proxy filing
Valion Bio filed a proxy statement on July 17, 2026, providing details for shareholder voting and corporate governance matters.
Valion Bio reports continued development of Entolimod program
Valion Bio (VBIO) reported across a series of strategic initiatives for its Entolimod program – including continued engagement with U.S. government agencies and allied nations on Acute Radiation Syndr...
Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion
Strategic execution across multiple initiatives positions the Entolimod platform to pursue opportunities in government preparedness, domestic biomanufacturing and oncology supportive care SAN ANTONIO,...
Valion Bio Proxy statement: Proxy filing
Valion Bio filed a proxy statement on July 7, 2026, providing details for shareholder voting and corporate governance matters.
AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS
AFRRI/NIAID partnership and validated animal models significantly derisk regulatory and commercial advancement of Company's lead candidate Positive momentum further positions Entolimod as a potential ...
Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures
Emanates from the FY27 NDAA process underway in the U.S. Congress Prioritizes radiation/nuclear countermeasures that are both prophylactic (radioprotectant) and therapeutic (radiomitigant) Follows Com...
Valion Bio Transcript: AGM 2026
The meeting marked the first under the new company name and focused on executing a biopharma strategy. All eight shareholder proposals, including director election and share issuances, were approved, with strong emphasis on clinical development and governance.
VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME
Cross-Agency Discussion Highlights Interest in Oral Formulation as Field-Deployable Medical Countermeasure SAN ANTONIO, May 19, 2026 /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO), a late-stage innat...
Valion Bio’s Velocity Bioworks licenses LarmorBio’s BioScan-NMR platform
Valion Bio’s (VBIO) wholly owned subsidiary, Velocity Bioworks, has entered into an exclusive commercial development and license agreement with LarmorBio for LarmorBio’s BioScan-NMR platform, a next-g...
Valion Bio reports Q1 EPS ($2.23) vs. ($2.52) last year
Cash and cash equivalents at March 31, 2026 totaled $7.2M vs. $12.6M at December 31, 2025. The company continues to evaluate capital alternatives to support continued execution against pipeline, regul...
Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform
First Commercial Installation Targeted for July 2026 in San Antonio; Strategic Reference Site Positions Velocity Bioworks at the Forefront of Next-Generation NMR-Based Diagnostics SAN ANTONIO, May 14,...